A61K 31/472
Non-condensed isoquinolines
Official title: Non-condensed isoquinolines, e.g. papaverine
A61K31/472 (Non-condensed isoquinolines) appears on 1,550 US grants and 2,897 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,550
- Published applications
- 2,897
- Assignees
- 1,179
- Inventors
- 7,277
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 5 | 0 |
| 1997 | 15 | 0 |
| 1998 | 12 | 0 |
| 1999 | 17 | 0 |
| 2000 | 19 | 0 |
| 2001 | 14 | 5 |
| 2002 | 21 | 23 |
| 2003 | 26 | 49 |
| 2004 | 7 | 51 |
| 2005 | 17 | 48 |
| 2006 | 19 | 49 |
| 2007 | 8 | 39 |
| 2008 | 17 | 45 |
| 2009 | 19 | 73 |
| 2010 | 25 | 86 |
| 2011 | 41 | 82 |
| 2012 | 45 | 87 |
| 2013 | 68 | 124 |
| 2014 | 95 | 169 |
| 2015 | 110 | 200 |
| 2016 | 105 | 168 |
| 2017 | 143 | 147 |
| 2018 | 96 | 139 |
| 2019 | 98 | 154 |
| 2020 | 94 | 121 |
| 2021 | 70 | 150 |
| 2022 | 75 | 131 |
| 2023 | 69 | 188 |
| 2024 | 54 | 195 |
| 2025 | 77 | 194 |
| 2026 | 61 | 180 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Multiparticulate pharmaceutical composition of tamsulosin and solifenacin8 Sep 2026US 12,728,106 B2Zim Laboratories Limited
- Coronavirus main protease inhibitors and methods using same8 Sep 2026US 12,729,190 B2Baylor College of Medicine
- 5-amino-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide derivatives as MTA-cooperative inhibitors of PRMT51 Sep 2026US 12,723,048 B2BeOne Medicines | GmbH
- Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor25 Aug 2026US 12,714,722 B2Fred Hutchinson Cancer Center
- ExoVII inhibitor and quinolone antibiotic combination useful for treating bacterial infection11 Aug 2026US 12,702,665 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Lifitegrast-containing ink binder for ophthalmic devices8 Oct 2026US 2026/0306478 A1Bausch + Lomb Ireland Limited
- Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors8 Oct 2026US 2026/0306505 A1BioAxone BioSciences, Inc.
- Triazolyl-containing compounds8 Oct 2026US 2026/0308146 A1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Surface modified ophthalmic devices1 Oct 2026US 2026/0294680 A1Bausch + Lomb Ireland Limited
Most cited
By later US patents
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof170US 7,074,801 B1Eisai Co., Ltd. · 2006
- Modulators of ATP-binding cassette transporters157US 7,495,103 B2Vertex Pharmaceuticals Incorporated · 2009
- Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase132US 5,656,643 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1997
- Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers124US 6,045,829 AElan Pharma International Limited · 2000